Al Malkinson the Scientist: Eulogy by Dr. Lori Dwyer-Nield
Aug16

Al Malkinson the Scientist: Eulogy by Dr. Lori Dwyer-Nield

In this second part of my remembrance of lung cancer biochemical pharmacologist, Colorado’s Dr. Al Malkinson, I’d like to share with readers some recollections by Lori Dwyer-Nield, PhD. I’ve known Lori since my appointment to Colorado’s faculty in 1992 when she had already been a postdoctoral fellow of Al’s. Dr. Dwyer-Nield continued on as research faculty at the CU School of Pharmacy and co-authored over...

Read More
Antibody-drug conjugates: not exactly “smart bombs” for cancer
Jun22

Antibody-drug conjugates: not exactly “smart bombs” for cancer

I only have a quick post today because I really want you to spend your reading energy on a superb C&EN cover story by my colleague here, Lisa M. Jarvis. The media frenzy that normally follows the American Society of Clinical Oncology (ASCO) meeting each June focused this year on cancer cell-directed antibodies conjugated to highly-cytotoxic compounds. The most ballyhooed of these is T-DM1, the anti-HER2 trastuzumab antibody...

Read More
Bad news for Bionovo and herbal drug development
Mar11

Bad news for Bionovo and herbal drug development

A pharmacognosy colleague contacted me on Friday morning with word that the botanical drug development company Bionovo was closing its chemistry group. Well, the news is actually worse as judging from this 8 pm Friday press release: Bionovo, Inc. (OTC Link Platform: BNVI.PK) today announced that it will need to obtain substantial additional funding to achieve its objectives of internally developing drugs. The Company reduced its...

Read More
FDA Withdraws Avastin Approval for Breast Cancer
Nov18

FDA Withdraws Avastin Approval for Breast Cancer

  As reported around the wires today, US FDA Commissioner Dr. Margaret A. Hamburg formally revoked the accelerated approval of the antiangiogenic drug Avastin (bevacizumab) for breast cancer treatment. Avastin is a humanized mouse antibody that binds and inactivates the vascular endothelial growth factor VEGF-A, a mediator of blood vessel growth. Andrew Pollack at The New York Times does a nice job condensing this episode for us....

Read More
Mike Kastan to lead Duke Cancer Institute
May16

Mike Kastan to lead Duke Cancer Institute

The NCI Comprehensive Cancer Center at Duke University has just announced that Michael Kastan, MD, PhD, will become its new executive director. Kastan currently serves as director of the cancer center at St. Jude Children’s Hospital in Memphis, a position he has held since 2004. A well-respected physician-scientist, Kastan oversaw St. Jude becoming the first pediatric cancer hospital to receive NCI comprehensive status. A start...

Read More
Winners in The Henrietta Lacks Foundation design contest
Apr08

Winners in The Henrietta Lacks Foundation design contest

First things first: Congratulations to Holly Gaskamp (hollycopter) and Michael Lombardi (Amoeba Mike)! Let me explain. The last two weeks have been a whirlwind while planning for the 102nd Annual Meeting of the American Association for Cancer Research (AACR) held April 2-6 in Orlando, Florida. Having been invited by author Rebecca Skloot to serve on the board of The Henrietta Lacks Foundation, we used our recently-awarded 501(c)(3)...

Read More